{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"22.2","upperLimit":"46.7","value":"34.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"}],"units":"Participants"}],"description":"Overall response rate=(PR+nCR+CR) CR= \\< 5% plasma cells in bone marrow. No confirmation on bone marrow plasma cell (additional assessment) is needed to document CR except patients with non-secretory myeloma where the bone marrow examination must be repeated after an interval of at least 6 weeks, Absence of M-protein in serum and urine by immunofixation,nCR same as CR without out Absence of M-protein in serum and urine by immunofixation,PR+ 50% reduction of serum M-protein and sofft tissue Plasmacytomas all for more than 6 weeks.","dispersionType":"95% Confidence Interval","groups":[{"description":"panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory multiple myeloma","id":"OG000","title":"Panobinostat + Bortezomib & Dexamethasone"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set","reportingStatus":"POSTED","timeFrame":"after eight cycyles of treatment (24 weeks)","title":"Overall Response Rate (PR+nCR+CR)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}